Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection

Inclusion Criteria: * Ages 18-65 (including boundary values), male or female. * At the time of screening, etiological or clinical or pathological evidence of hepatitis B virus infection has been more than 1 year; HBsAg positive, 10 IU/mL \<HBV DNA≤2000 IU/mL, ALT≤3×ULN (upper limit of normal); No obvious cirrhosis was found by the researchers. * Continuous administration of any nucleoside (acid) analogues for more than 1 year and a stable regimen of ≥6 months prior to screening. * Able to communicate well with researchers, understand and comply with the requirements of the study, understand and sign the informed consent. * Male subjects with fertile female partners or female subjects of childbearing age were willing to voluntarily take effective contraceptive measures within 3 months after screening. Exclusion Criteria: * Pregnant (positive pregnancy test) or breastfeeding women. * Co-infection with other viruses such as hepatitis A virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, human immunodeficiency virus, syphilis. * A history of cirrhosis or evidence of significant fibrosis or cirrhosis at pre-screening/screening time. * The subject had a history of hepatocellular carcinoma (HCC) before or at the time of screening, or was suspected of HCC. * A history of malignant tumors within 5 years prior to screening, except for certain cancers that can be completely cured by surgical resection. * Subjects with other chronic liver diseases, including but not limite…